Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Tharimmune, Inc. THAR NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Tharimmune, Inc. (THAR) is a Biotechnology company in the Healthcare sector, currently trading at $3.39. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: THAR trades at a trailing Price-to-Earnings (P/E) of -2.9 (S&P 500 average ~25).

Net income is $36M (loss), growing at -78.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $398M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.29 (strong liquidity). Debt-to-assets is 0%. Total assets: $519M.

Analyst outlook: 0 / 1 analysts rate THAR as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

THAR SharesGrow Score Overview

33/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — THAR

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
THAR: +0%/yr revenue is, -78.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet THAR: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.29 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
THAR: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 1 analysts rate THAR as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.952-9.08
Volume900.66K
Avg Volume (30D)807.86K
Market Cap$134.01M
Beta (1Y)1.45
Share Statistics
EPS (TTM)-1.12
Shares Outstanding$32.05M
IPO Date2022-01-12
Employees2
CEOMark Wendland
Financial Highlights & Ratios
EBITDA$-42.08M
Net Income$-35.92M
Operating Income$-20.11M
Total Cash$17.03M
Net Debt$-17.03M
Total Assets$519.15M
Price / Earnings (P/E)-3
Analyst Forecast
Rating ConsensusHold
Analysts Covering1
Buy 0% Hold 100% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS4327053090

Price Chart

Track all markets on TradingView
THAR
Tharimmune, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.95 52WK RANGE 9.08

People Also View

ANL
ANL
Adlai Nortye Ltd.
$13.62
-13.14%
 ADAP
ADAP
Adaptimmune Therapeutics plc
$0.05
-3.00%
 APLM
APLM
Apollomics, Inc.
$14.27
-6.12%
 ICU
ICU
SeaStar Medical Holding Corporation
$3.86
+2.93%
 BLRX
BLRX
BioLineRx Ltd.
$2.38
-0.84%
 AIMD
AIMD
Ainos, Inc.
$1.61
-2.42%
 LNAI
LNAI
Lunai Bioworks Inc.
$0.32
-4.69%
 MBRX
MBRX
Moleculin Biotech, Inc.
$2.44
-2.01%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message